NLSPW Stock Price, Chart, Stats & News
NLS Pharmaceutics AG (NLSPW) does not currently pay a dividend.
NLSPW chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -49.93% |
ROE | -100.99% |
D/E | – |
Interest coverage ratio | -64.74x |
NLSPW valuation
P/E | – |
P/S | – |
P/B | 0.31x |
P/CF | -0.18x |
P/FCF | -0.21x |
P/OCF | -0.18x |
PEG | 0.01x |
EV multiple | -1.07x |
About
NLS Pharmaceutics AG is a biopharmaceutical firm currently in its clinical development phase, concentrating on identifying and advancing therapeutic interventions for individuals affected by complex and uncommon conditions impacting the central nervous system (CNS). The company's research and development primarily target narcolepsy, idiopathic hypersomnia, and various other infrequent sleep disorders, alongside neurodevelopmental conditions like attention deficit hyperactivity disorder (ADHD). Key product candidates in their pipeline include Quilience, designed to alleviate excessive daytime drowsiness and cataplexy, and Nolazol, which aims to treat ADHD.
Similar securities
Based on sector and market capitalization
